AbbVie (NYSE: ABBV), which completed the acquisition of Allergan on May 8, 2020, reported second quarter 2020 earnings results today. The company's
AbbVie (NYSE: ABBV), which is expecting to close the acquisition of Allergan in this month, reported its first quarter 2020 earnings results
AbbVie Inc (ABBV) Q1 2020 earnings call dated May. 01, 2020 Corporate Participants: Liz Shea -- Vice President, Investor Relations Richard A. Gonzalez -- Chairman of
AbbVie (NYSE: ABBV) reported its first quarter 2020 earnings results, which surpassed the market's views. Adjusted EPS of $2.42 and revenue of
AbbVie Inc (NYSE: ABBV) Q4 2019 Earnings Conference Call February 07, 2020 Corporate Participants: Liz Shea -- Vice President of Investor Relations Richard A. Gonzalez -- Chairman
For some of the leading drugmakers, currently, the first priority is to find an effective treatment for Covid-19, which was declared a
AbbVie (NYSE: ABBV) topped revenue and earnings expectations for the fourth quarter of 2019, allowing the stock to gain over 3% in
With only a few weeks left for closing the high-value acquisition of Allergan, AbbVie (NYSE: ABBV) is busy doing the groundwork for
AbbVie Inc. (NYSE: ABBV) reported a 31% dip in earnings for the third quarter of 2019 due to higher costs and expenses.
Allergan plc (NYSE: AGN) continued to dominate in the tissue expander market as the demand for plastic surgeries is increasing from the
AbbVie's (NYSE: ABBV) earnings and revenue for the second quarter of 2019 surpassed Wall Street's estimates. AbbVie reported adjusted EPS of $2.26
AbbVie (NYSE: ABBV) is scheduled to report its earnings results for the second quarter of 2019 on Friday before the market opens.
Confirming reports published by Wall Street Journal earlier today, pharmaceutical giant Abbvie (NYSE: ABBV) said it would acquire Irish competitor Allergan (NYSE:
Abbvie (NYSE: ABBV) is one of the worse performing pharma stocks in the trailing 12-month period. The stock has declined almost 19%
AbbVie Inc. (NYSE: ABBV) surpassed market estimates on revenue and earnings for the first quarter of 2019, giving shares a lift of
The general market sentiment on Merck & Co. (MRK) is quite bullish ahead of the drug maker’s fourth-quarter earnings report. Analysts predict
AbbVie Inc. (ABBV) slipped to a loss in the fourth quarter from a profit last year, due to the inclusion of the
A slew of major companies are reporting earnings this week. Healthcare giant Johnson & Johnson (JNJ) will announce fourth-quarter earnings on Tuesday
US pharma giant AbbVie Inc (ABBV) cut its overseas sales forecast on Friday for its offering Humira, on expected pricing cuts to
AbbVie Inc. (ABBV) reported a 68% jump in earnings for the third quarter helped by sales growth from Humira, Imbruvica, and HCV.